Seeking Alpha

Richard Daifuku

ABOUT
Richard Daifuku MD-PhD has over 20 years experience in the biotechnology industry, with experience in multiple roles, including Chief Medical Officer, Chief Scientific Officer and Chief Executive Officer. He has multiple issued and pending patents for small molecules for the treatment of HIV and cancer. He is currently a consultant for Phase 1two3.
SNAPSHOT
  • Description: Occasional Investor. Trading frequency: Weekly
  • Interests: Stocks - long
COMPANY
Phase 1two3 Evaluations of biopharmaceutical events are posted from time to time on the company website in the "news" section.
BLOG
Currently, you have no blog details. Click edit to add blog details.
Book
Currently, you have no book details. Click edit to add book details.
LATEST STOCKTALK more »
What Is The Significance Of Thromboembolic Events For The Future Of Halozyme Therapeutics' PEGPH20? $HALO http://seekingalpha.com/a/19nhx Apr 7, 2014